Drugs

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original clinical research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

Contact: For more information about the journal, including pre-submission enquiries, please contact Sue Pochon at [email protected]